Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
NanobiotixS. A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
NanobiotixS. A. was incorporated in 2003 and is based in Paris, France.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 24, 25 | 0.00 Increased by +100.00% | -0.35 Increased by +100.00% |
| Apr 2, 25 | -0.98 Decreased by N/A% | -0.73 Decreased by -33.86% |
| Nov 29, 24 | 0.00 Decreased by N/A% | - |
| Sep 18, 24 | -0.50 Decreased by N/A% | -0.51 Increased by +1.90% |
| Apr 24, 24 | -0.13 Decreased by N/A% | -0.13 Increased by +1.08% |
| Nov 13, 23 | 0.00 Decreased by N/A% | - |
| Sep 26, 23 | 0.00 Decreased by N/A% | -0.85 Increased by +100.00% |
| Apr 24, 23 | 0.00 Decreased by N/A% | -0.75 Increased by +100.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | -20.90 M Decreased by -734.62% | -46.26 M Decreased by -64.63% | Increased by +221.36% Increased by +125.94% |
| Jun 30, 24 | 9.29 M Increased by +438.96% | -21.87 M Increased by +28.72% | Decreased by -235.46% Increased by +86.77% |
| Mar 31, 24 | 32.91 M Increased by +N/A% | -11.60 M Decreased by N/A% | Decreased by -35.25% - |
| Sep 30, 23 | 16.46 M Increased by +854.89% | -5.80 M Increased by +62.19% | Decreased by -35.25% Increased by +96.04% |
| Jun 30, 23 | 3.29 M Increased by +395.56% | -28.10 M Decreased by -6.61% | Decreased by -853.29% Increased by +78.49% |
| Mar 31, 23 | 1.72 M Increased by +159.56% | -30.68 M Decreased by -85.03% | Decreased by -1.78 K% Increased by +28.71% |
| Dec 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Sep 30, 22 | 1.72 M Increased by +N/A% | -15.34 M Decreased by N/A% | Decreased by -890.17% - |